Reducing Single-Use Vial Waste May Require Regulatory Action

The National Academies of Sciences, Engineering, and Medicine, while acknowledging that payers are concerned about waste and extra expense that may occur when some of the medication in a single-use vial is discarded, says there’s little private payers can do to help offset this waste. In fact, it’s urging CMS to discontinue the requirement that providers report data on unused medication, while also recommending several regulatory steps that it says could help the overall cost problem.

The congressionally mandated report from the National Academies notes that many of these drugs are among the most expensive on the market. But the excess portions of single-dose vials that are discarded don’t necessarily represent waste at all, says study committee chair Edward Shortliffe, M.D., Ph.D., chair emeritus and adjunct professor at Columbia University’s Department of Biomedical Informatics.

© 2024 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

Optum sign
September 11

UnitedHealth Will Reduce Humira Coverage, Cover Stelara Biosimilar

READ MORE
pill-bottle
August 22

Payers Eye Rebate Leverage, UM in Response to Medicare-Negotiated Drug Prices

READ MORE
drugs-in-an-envelope
August 22

Mark Cuban Cost Plus Drugs’ Biggest Benefit May Be Transparency, not Savings

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today